TRVI
Income statement / Annual
Last year (2023), Trevi Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Trevi Therapeutics, Inc.'s net income was -$29.07 M.
See Trevi Therapeutics, Inc.�s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$123,000.00 |
$43,000.00 |
$50,000.00 |
$47,000.00 |
$39,000.00 |
$23,000.00 |
$0.00 |
$4,000.00 |
Gross Profit |
-$123,000.00 |
-$43,000.00 |
-$50,000.00 |
-$47,000.00 |
-$39,000.00 |
-$23,000.00 |
$0.00 |
-$4,000.00 |
Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$23.68 M
|
$19.83 M
|
$22.98 M
|
$22.33 M
|
$19.34 M
|
$14.07 M
|
$6.10 M
|
$6.91 M
|
General & Administrative
Expenses |
$9.95 M
|
$10.07 M
|
$9.49 M
|
$10.16 M
|
$7.31 M
|
$4.34 M
|
$2.14 M
|
$1.66 M
|
Selling & Marketing
Expenses |
$287,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$50,000.00
|
Selling, General &
Administrative Expenses |
$10.24 M
|
$10.07 M
|
$9.49 M
|
$10.16 M
|
$7.31 M
|
$4.34 M
|
$2.14 M
|
$1.71 M
|
Other Expenses |
$0.00 |
$719,000.00 |
-$375,000.00 |
-$287,000.00 |
$577,000.00 |
-$2.24 M |
-$24,000.00 |
$0.00 |
Operating Expenses |
$33.92 M |
$29.91 M |
$32.48 M |
$32.49 M |
$26.65 M |
$18.41 M |
$8.24 M |
$8.62 M |
Cost And Expenses |
$33.92 M |
$29.91 M |
$32.48 M |
$32.49 M |
$26.65 M |
$18.41 M |
$8.24 M |
$8.63 M |
Interest Income |
$4.75 M |
$1.74 M |
$10,000.00 |
$178,000.00 |
$792,000.00 |
$156,000.00 |
$69,000.00 |
$2.61 M |
Interest Expense |
$391,000.00 |
$780,000.00 |
$1.20 M |
$456,000.00 |
$0.00 |
$174,000.00 |
$3.34 M |
$0.00 |
Depreciation &
Amortization |
$123,000.00
|
$43,000.00
|
$50,000.00
|
$47,000.00
|
$39,000.00
|
$23,000.00
|
$4,000.00
|
$4,000.00
|
EBITDA |
-$33.80 M
|
-$29.86 M
|
-$32.43 M
|
-$32.44 M
|
-$26.61 M
|
-$18.39 M
|
-$8.19 M
|
-$8.62 M
|
EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
$4.83 M
|
$719,000.00
|
-$1.49 M
|
-$287,000.00
|
$577,000.00
|
-$2.26 M
|
-$4.65 M
|
-$2.47 M
|
Income Before Tax |
-$29.10 M |
-$29.19 M |
-$33.96 M |
-$32.78 M |
-$26.07 M |
-$20.67 M |
-$12.89 M |
-$11.10 M |
Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$32,000.00 |
-$36,000.00 |
-$21,000.00 |
-$18,000.00 |
-$18,000.00 |
-$124,000.00 |
-$26,000.00 |
-$8,000.00 |
Net Income |
-$29.07 M |
-$29.15 M |
-$33.94 M |
-$32.76 M |
-$26.05 M |
-$20.55 M |
-$12.86 M |
-$11.09 M |
Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
EPS |
-0.29 |
-0.45 |
-1.49 |
-1.81 |
-2.22 |
-2.29 |
-1.43 |
-0.69 |
EPS Diluted |
-0.29 |
-0.45 |
-1.49 |
-1.81 |
-2.22 |
-2.29 |
-1.43 |
-0.69 |
Weighted Average Shares
Out |
$99.03 M
|
$64.54 M
|
$22.84 M
|
$18.06 M
|
$11.74 M
|
$8.97 M
|
$8.97 M
|
$16.14 M
|
Weighted Average Shares
Out Diluted |
$99.03 M
|
$64.54 M
|
$22.84 M
|
$18.06 M
|
$11.74 M
|
$8.97 M
|
$8.97 M
|
$16.14 M
|
Link |
|
|
|
|
|
|
|
|